Canaccord Genuity Keeps 'Buy' Rating for Clover Health Investments with Unchanged Price Target of $3.70

Canaccord Genuity maintains a "Buy" rating and price target of $3.70 for Clover Health Investments (CLOV). The analyst, Richard Close, has confidence in the current valuation and future outlook of the company. The average target price for CLOV is $3.23, with an upside of 25.81% from the current price. The estimated GF Value for CLOV in one year is $4.41, suggesting a 71.6% upside from the current price.